Boston Scientific Corporation $BSX Shares Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 205,857 shares of the medical equipment provider’s stock after acquiring an additional 3,790 shares during the quarter. New York Life Investment Management LLC’s holdings in Boston Scientific were worth $22,111,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the period. Diversified Trust Co boosted its position in shares of Boston Scientific by 15.9% in the first quarter. Diversified Trust Co now owns 5,236 shares of the medical equipment provider’s stock worth $528,000 after buying an additional 718 shares during the period. Essex Financial Services Inc. boosted its position in shares of Boston Scientific by 13.6% in the first quarter. Essex Financial Services Inc. now owns 2,977 shares of the medical equipment provider’s stock worth $300,000 after buying an additional 356 shares during the period. Amalgamated Bank boosted its position in shares of Boston Scientific by 1.0% in the first quarter. Amalgamated Bank now owns 292,440 shares of the medical equipment provider’s stock worth $29,501,000 after buying an additional 2,906 shares during the period. Finally, Valley National Advisers Inc. boosted its position in shares of Boston Scientific by 152.4% in the first quarter. Valley National Advisers Inc. now owns 997 shares of the medical equipment provider’s stock worth $100,000 after buying an additional 602 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 167,313 shares of company stock valued at $17,237,959 in the last ninety days. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Truist Financial raised their target price on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $102.43 on Tuesday. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The business has a 50-day moving average of $101.13 and a two-hundred day moving average of $102.16. The stock has a market capitalization of $151.77 billion, a P/E ratio of 54.77, a P/E/G ratio of 2.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.